EXACT Sciences Co. (EXAS) Given Average Recommendation of “Buy” by Analysts

EXACT Sciences Co. (NASDAQ:EXAS) has been given a consensus rating of “Buy” by the sixteen research firms that are currently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $88.20.

Several brokerages recently commented on EXAS. Benchmark reiterated a “hold” rating on shares of EXACT Sciences in a research note on Wednesday, September 5th. Cowen raised their price objective on shares of EXACT Sciences from $65.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, September 5th. Craig Hallum raised their price objective on shares of EXACT Sciences from $54.00 to $74.00 and gave the company a “buy” rating in a research note on Thursday, August 23rd. BidaskClub cut shares of EXACT Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 26th. Finally, Zacks Investment Research upgraded shares of EXACT Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, August 21st.

In other EXACT Sciences news, insider D Scott Coward sold 2,190 shares of EXACT Sciences stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $79.51, for a total transaction of $174,126.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Graham Peter Lidgard sold 38,311 shares of EXACT Sciences stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $75.01, for a total transaction of $2,873,708.11. Following the transaction, the insider now owns 29,398 shares of the company’s stock, valued at approximately $2,205,143.98. The disclosure for this sale can be found here. Insiders have sold a total of 218,255 shares of company stock valued at $15,791,740 in the last ninety days. Corporate insiders own 3.20% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Zevenbergen Capital Investments LLC raised its position in shares of EXACT Sciences by 1.8% during the 2nd quarter. Zevenbergen Capital Investments LLC now owns 2,070,170 shares of the medical research company’s stock worth $123,775,000 after purchasing an additional 35,725 shares during the last quarter. Artisan Partners Limited Partnership raised its holdings in shares of EXACT Sciences by 25.8% in the second quarter. Artisan Partners Limited Partnership now owns 1,879,525 shares of the medical research company’s stock worth $112,377,000 after acquiring an additional 385,766 shares during the last quarter. Frontier Capital Management Co. LLC raised its holdings in shares of EXACT Sciences by 37.7% in the third quarter. Frontier Capital Management Co. LLC now owns 1,585,851 shares of the medical research company’s stock worth $125,155,000 after acquiring an additional 434,184 shares during the last quarter. Eagle Asset Management Inc. raised its holdings in shares of EXACT Sciences by 46.3% in the third quarter. Eagle Asset Management Inc. now owns 1,227,683 shares of the medical research company’s stock worth $96,888,000 after acquiring an additional 388,434 shares during the last quarter. Finally, Jennison Associates LLC raised its holdings in shares of EXACT Sciences by 19.3% in the third quarter. Jennison Associates LLC now owns 1,152,986 shares of the medical research company’s stock worth $90,994,000 after acquiring an additional 186,726 shares during the last quarter. Institutional investors own 87.06% of the company’s stock.

Shares of EXAS traded down $1.46 during mid-day trading on Monday, hitting $74.62. The company’s stock had a trading volume of 1,932,975 shares, compared to its average volume of 2,147,434. EXACT Sciences has a 1-year low of $37.36 and a 1-year high of $81.22. The company has a debt-to-equity ratio of 0.94, a current ratio of 12.08 and a quick ratio of 11.72. The stock has a market capitalization of $9.28 billion, a P/E ratio of -75.37 and a beta of 1.21.

EXACT Sciences (NASDAQ:EXAS) last released its earnings results on Tuesday, October 30th. The medical research company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. EXACT Sciences had a negative return on equity of 20.18% and a negative net margin of 35.83%. The company had revenue of $118.29 million during the quarter, compared to the consensus estimate of $109.33 million. During the same quarter last year, the company earned ($0.23) earnings per share. EXACT Sciences’s quarterly revenue was up 63.0% compared to the same quarter last year. Research analysts anticipate that EXACT Sciences will post -1.53 EPS for the current year.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Featured Story: How do investors use RSI to grade stocks?

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply